Cansino Biologics Stock Performance
| CASBF Stock | USD 3.37 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.16, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CanSino Biologics are expected to decrease at a much lower rate. During the bear market, CanSino Biologics is likely to outperform the market. At this point, CanSino Biologics has a negative expected return of -0.0102%. Please make sure to confirm CanSino Biologics' maximum drawdown, as well as the relationship between the skewness and day median price , to decide if CanSino Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CanSino Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, CanSino Biologics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 4.4 B | |
| Total Cashflows From Investing Activities | -2.6 B |
CanSino |
CanSino Biologics Relative Risk vs. Return Landscape
If you would invest 351.00 in CanSino Biologics on November 3, 2024 and sell it today you would lose (14.00) from holding CanSino Biologics or give up 3.99% of portfolio value over 90 days. CanSino Biologics is currently producing negative expected returns and takes up 3.4636% volatility of returns over 90 trading days. Put another way, 30% of traded pink sheets are less volatile than CanSino, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CanSino Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CanSino Biologics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as CanSino Biologics, and traders can use it to determine the average amount a CanSino Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.003
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CASBF |
Estimated Market Risk
| 3.46 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CanSino Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CanSino Biologics by adding CanSino Biologics to a well-diversified portfolio.
CanSino Biologics Fundamentals Growth
CanSino Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CanSino Biologics, and CanSino Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CanSino Pink Sheet performance.
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 3.58 B | |||
| Shares Outstanding | 114.78 M | |||
| Price To Earning | 19.25 X | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 2.51 X | |||
| Revenue | 4.3 B | |||
| EBITDA | 2.05 B | |||
| Cash And Equivalents | 7 B | |||
| Cash Per Share | 28.36 X | |||
| Total Debt | 40 M | |||
| Debt To Equity | 0.26 % | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.59 X | |||
| Total Asset | 11.87 B | |||
About CanSino Biologics Performance
By analyzing CanSino Biologics' fundamental ratios, stakeholders can gain valuable insights into CanSino Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CanSino Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CanSino Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2191 people.Things to note about CanSino Biologics performance evaluation
Checking the ongoing alerts about CanSino Biologics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CanSino Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CanSino Biologics generated a negative expected return over the last 90 days | |
| CanSino Biologics has high historical volatility and very poor performance | |
| About 27.0% of the company shares are held by company insiders |
- Analyzing CanSino Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CanSino Biologics' stock is overvalued or undervalued compared to its peers.
- Examining CanSino Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CanSino Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CanSino Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CanSino Biologics' pink sheet. These opinions can provide insight into CanSino Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CanSino Pink Sheet analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |